<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088868</url>
  </required_header>
  <id_info>
    <org_study_id>040218</org_study_id>
    <secondary_id>04-C-0218</secondary_id>
    <secondary_id>NCI-6544</secondary_id>
    <secondary_id>CDR0000377488</secondary_id>
    <nct_id>NCT00088868</nct_id>
    <nct_alias>NCT00086008</nct_alias>
  </id_info>
  <brief_title>17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma</brief_title>
  <official_title>A Phase I Study Of 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) With Evaluation Of Hsp90 Client Proteins In Subjects With Solid Tumors And Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as&#xD;
      17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop&#xD;
      cancer cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of 17-DMAG in treating&#xD;
      patients with an advanced solid tumor or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of&#xD;
           17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in patients with an&#xD;
           advanced malignant solid tumor or lymphoma.&#xD;
&#xD;
        -  Determine the dose-limiting toxic effects and toxicity profile of this drug in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the effects of this drug on heat shock protein 90 (Hsp90) client proteins when&#xD;
           assayed in peripheral blood mononuclear cells (PBMC) vs tumor tissue from patients&#xD;
           treated with this drug.&#xD;
&#xD;
        -  Correlate disturbances in key signaling pathways with administration of this drug in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the dose that alters key proteins in the majority of patients treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Correlate serum proteomic patterns with target interactions or DMAG clinical effects in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a single-center, dose-escalation study.&#xD;
&#xD;
      Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-2&#xD;
      hour on days 1 and 4 or days 2 and 5 weekly for 4 weeks. Treatment repeats every 4 weeks in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of 17-DMAG until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of up to 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional&#xD;
      patients are treated at the MTD.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lymphoma</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvespimycin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant solid tumor OR lymphoma&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Standard curative or palliative measures are not available OR are associated with&#xD;
             minimal survival benefit&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
               -  Treated brain metastases allowed provided they have been stable ≥ 6 months&#xD;
                  without steroids or anti-seizure medications&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times normal&#xD;
&#xD;
          -  PT and PTT ≤ 1.5 times normal (unless due to the presence of lupus anticoagulant or&#xD;
             stable anticoagulation)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No orthostatic hypotension &gt; grade 2 (requiring more than brief fluid replacement or&#xD;
             other therapy OR with physiological consequences)&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  LVEF ≥ 40% by MUGA&#xD;
&#xD;
          -  QTc ≤ 450 msec (470 msec for women)&#xD;
&#xD;
          -  No congenital long QT syndrome&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No active ischemic heart disease within the past year&#xD;
&#xD;
          -  No history of uncontrolled dysrhythmias&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (ventricular fibrillation or ventricular&#xD;
             tachycardia &gt; 3 premature ventricular contractions in a row)&#xD;
&#xD;
          -  Not requiring antiarrhythmic drugs&#xD;
&#xD;
          -  No poorly controlled angina&#xD;
&#xD;
          -  No left bundle branch block&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No uncontrolled symptomatic pulmonary disease, including any of the following:&#xD;
&#xD;
               -  Dyspnea off or on exertion&#xD;
&#xD;
               -  Paroxysmal nocturnal dyspnea&#xD;
&#xD;
               -  Severe chronic obstructive/restrictive pulmonary disease requiring daily chronic&#xD;
                  medications and oxygen&#xD;
&#xD;
          -  Must not meet the Medicare criteria for home oxygen&#xD;
&#xD;
          -  No sufficiently compromised pulmonary status as measured by baseline pulmonary&#xD;
             function tests and DLCO&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             participation&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No hyponatremia indicated by sodium &lt; 130 mmol/L&#xD;
&#xD;
          -  No known immunodeficiency syndromes&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to 17-dimethylaminoethylamino-17-demethoxygeldanamycin&#xD;
             (geldanamycin or 17-AAG)&#xD;
&#xD;
          -  No concurrent uncontrolled illness&#xD;
&#xD;
          -  No active or ongoing uncontrolled infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy and recovered&#xD;
&#xD;
          -  No concurrent prophylactic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin, 8&#xD;
             weeks for UCN-01) and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent hormonal therapy for prostate cancer allowed provided patient has&#xD;
             metastatic disease that has progressed despite prior hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy that included the heart in the field (e.g., mantle radiotherapy)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since prior participation in a phase 0 study&#xD;
&#xD;
          -  Concurrent bisphosphonates for any cancer allowed&#xD;
&#xD;
          -  Concurrent preventative doses of aspirin or non-steroidal anti-inflammatory drugs&#xD;
             allowed&#xD;
&#xD;
          -  No concurrent drugs that may prolong QTc interval&#xD;
&#xD;
          -  No concurrent full anticoagulation on a regular basis&#xD;
&#xD;
          -  No concurrent prophylactic antiemetics&#xD;
&#xD;
          -  No other concurrent investigational agents or therapies&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shivaani Kummar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Medical Oncology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

